Indosolar Limited (BOM:533257)
India · Delayed Price · Currency is INR 377.90
+17.95 (4.99%)
At close: Aug 8, 2025
Verve Therapeutics Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Operating Revenue | 5,186 | 3,239 | - | - | - | - | Upgrade |
Other Revenue | - | - | - | - | 1.91 | 6.53 | Upgrade |
| 5,186 | 3,239 | - | - | 1.91 | 6.53 | Upgrade | |
Revenue Growth (YoY) | 57965.38% | - | - | - | -70.83% | - | Upgrade |
Cost of Revenue | 3,429 | 2,170 | - | - | - | - | Upgrade |
Gross Profit | 1,757 | 1,069 | - | - | 1.91 | 6.53 | Upgrade |
Selling, General & Admin | 42.01 | 30.6 | 0.56 | 0.21 | 2 | 2.56 | Upgrade |
Other Operating Expenses | 119.43 | 87.59 | 13.18 | 9.83 | 77.25 | 11.98 | Upgrade |
Operating Expenses | 518.26 | 391.48 | 59.56 | 52.55 | 150.3 | 86.02 | Upgrade |
Operating Income | 1,239 | 677.16 | -59.56 | -52.55 | -148.39 | -79.49 | Upgrade |
Interest Expense | -110.42 | -137.78 | -69.97 | -11.03 | -0 | -0.02 | Upgrade |
Interest & Investment Income | - | - | 1.42 | 1.4 | - | - | Upgrade |
Currency Exchange Gain (Loss) | - | - | 5.41 | 0.01 | - | - | Upgrade |
Other Non Operating Income (Expenses) | 20.59 | 8.39 | -7.72 | - | 0 | - | Upgrade |
EBT Excluding Unusual Items | 1,149 | 547.77 | -130.42 | -62.16 | -148.39 | -79.5 | Upgrade |
Asset Writedown | - | - | -24.82 | -493.86 | -1,075 | - | Upgrade |
Other Unusual Items | - | - | 0.8 | 11,370 | - | - | Upgrade |
Pretax Income | 1,149 | 547.77 | -154.44 | 10,814 | -1,223 | -79.5 | Upgrade |
Income Tax Expense | -616.4 | -0.05 | - | 2.36 | - | - | Upgrade |
Net Income | 1,766 | 547.82 | -154.44 | 10,812 | -1,223 | -79.5 | Upgrade |
Net Income to Common | 1,766 | 547.82 | -154.44 | 10,812 | -1,223 | -79.5 | Upgrade |
Shares Outstanding (Basic) | 42 | 42 | 42 | 61 | 4 | 4 | Upgrade |
Shares Outstanding (Diluted) | 42 | 42 | 42 | 61 | 4 | 4 | Upgrade |
Shares Change (YoY) | 13.51% | -0.07% | -31.33% | 1530.43% | -1.79% | -0.15% | Upgrade |
EPS (Basic) | 42.42 | 13.17 | -3.71 | 178.36 | -329.00 | -21.00 | Upgrade |
EPS (Diluted) | 42.42 | 13.17 | -3.71 | 178.36 | -329.00 | -21.00 | Upgrade |
Free Cash Flow | - | 644.76 | -417.32 | -181.06 | -4.85 | -6.2 | Upgrade |
Free Cash Flow Per Share | - | 15.50 | -10.03 | -2.99 | -1.30 | -1.64 | Upgrade |
Gross Margin | 33.89% | 32.99% | - | - | 100.00% | 100.00% | Upgrade |
Operating Margin | 23.89% | 20.91% | - | - | -7789.50% | -1217.24% | Upgrade |
Profit Margin | 34.05% | 16.91% | - | - | -64208.82% | -1217.47% | Upgrade |
Free Cash Flow Margin | - | 19.91% | - | - | -254.49% | -94.99% | Upgrade |
EBITDA | 1,570 | 950.45 | -16.67 | -12.97 | -77.34 | -8.01 | Upgrade |
EBITDA Margin | 30.27% | 29.34% | - | - | - | -122.63% | Upgrade |
D&A For EBITDA | 330.89 | 273.29 | 42.89 | 39.58 | 71.05 | 71.48 | Upgrade |
EBIT | 1,239 | 677.16 | -59.56 | -52.55 | -148.39 | -79.49 | Upgrade |
EBIT Margin | 23.89% | 20.91% | - | - | - | - | Upgrade |
Effective Tax Rate | - | - | - | 0.02% | - | - | Upgrade |
Revenue as Reported | 5,206 | 3,247 | 8.5 | 11.31 | 1.91 | 6.53 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.